Compounds and compositions as protein kinase inhibitors

摘要

The invention provides compounds of Formula I: wherein R1-R6 are described in the Summary of the Invention; the pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, b-RAF, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKKα, IKK&bgr;, JNK2α2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR&bgr;, PKA, PKBα, PKD2, Rsk1, SAPK2α, SAPK2&bgr;, SAPK3, SGK, Tie2 and TrkB kinases.